The Best Penny Stocks to Buy This Week? 10 With potential biotechnological catalysts
We’re starting another week, and penny stocks are one of the hot topics among retail traders. But what if you knew certain things before they happened? What if you had a way of knowing when a company was going to present data or when management would attend conferences? Well, you’re in luck because specific industries offer just that. Today we’ll take a look at the biotech industry and some of the companies that have announced in detail why this week could be important.
PennyStocks.com – PennyStocks
Biotech stocks are among the few to offer a glimpse of the future, in layman’s terms. Since many of these companies are involved in ongoing trials, they will inform the public of the schedule and, therefore, the outlook as to when they expect to reveal the results. There are also firm dates for watchdogs like the FDA to give the green light for new phases of these trials, new applications, etc. So if you are looking for biotech penny stocks to buy, doing a little research can give you a head start when it comes to preparing your trading strategy.
Penny Stocks to Watch
- Evofem Biosciences Inc. (NASDAQ: EVFM)
- Arbutus Biopharma Corporation (NASDAQ: ABUS)
- Adverum Biotechnologies Inc. (NASDAQ: ADVM)
- Enveric Biosciences Inc. (NASDAQ: ENVB)
- Aditxt Inc. (NASDAQ: ADTX)
Evofem Biosciences Inc. (NASDAQ: EVFM)
If you’ve read some of our articles on penny stocks under $ 1, Evofem is probably a company you’ve come across recently. She specializes in female contraception. Evofem’s portfolio also includes its first FDA-approved product, Phexxi®. The company has presented a series of summaries all centered around the platform over the past few weeks. In addition, Evofem has also started advancing its EVO100 platform in the treatment of chlamydia and gonorrhea.
What to watch with EVFM Stock this week
This week, Evofem continues its circuit of presentations. On October 12, the company will attend the LD Micro Investor Conference, and CEO Saundra Pelletier will also host one-on-one meetings. Additionally, if EVFM stock is on your list, next week could also be an important week for the company. We will probably report the details again.
Read more: Best Penny Stocks To Buy According To Analysts And Goals Up To 290%
However, to give you an overview, the company is providing details of many abstracts at the Scientific Congress of the American Society for Reproductive Medicine on October 20, as well as more information provided at the XXIII World Congress of Obstetrics and Gynecology. from the International Federation of Gynecology and Obstetrics.
Arbutus Biopharma Corporation (NASDAQ: ABUS)
Arbutus’ actions have been the center of attention in recent weeks. The company specializes in the development of treatments against chronic infections. This includes hepatitis B and even new therapies to treat coronaviruses. It would appear that the company continues to have some milestone events to discuss. Last week, Arbutus presented its first of 2 conferences scheduled at the Chardan Genetic Medicines Conference.
He also presented arguments on Oct. 7 to the United States Court of Appeals for the Federal Circuit. This was in response to ongoing issues with Moderna (NASDAQ: MRNA). They conflict over Arbutus lipid formulations for delivery of nucleic acids.
What to watch with ABUS Stock this week
This week, the ABUS action will be in the spotlight as it will be presented at another conference. Following the events of the past week, investors may have October 13 on their calendar right now. That’s when management shows up to HC Wainwright Hepatitis B Virus.
Adverum Biotechnologies Inc. (NASDAQ: ADVM)
Another biotech penny stocks to watch was Adverum last week. The company is developing gene therapies with a primary focus on its lead candidate, ADVM-022. Last week, the company presented data from its 2-year OPTIC study at the Retina Society’s annual meeting. This was specific to the treatment of patients with wet age-related macular degeneration (AMD).
The results showed a reduction of more than 80% in the annualized frequency of anti-VEGF injections and a robust response sustained for 2 years. Additionally, this weekend, the company delivered Phase 2 data from its INFINITY trial targeting diabetic macular edema patients treated with ADVM-022. Given that we could probably see how the market reacts once things open on Monday, this might be something to keep in mind with ADVM stock.
What to watch with ADVM Stock this week
It’s not the only thing to watch this week either. Adverum presents the results of its phase 1 OPTIC trial in patients with neovascular AMD treated with ADVM-022. In particular, if ADVM stock is on your list, October 11 will be the day to remember. The company begins its presentation at 9:50 a.m.ET at the ASRS Scientific Meeting.
Enveric Biosciences Inc. (NASDAQ: ENVB)
If you’ve been following the trend of “alternative” biotech stocks, Enveric might be one you’ve come across recently. This is because the company is focusing its model more on mental health. Enveric closed its acquisition of MagicMed last week, creating a new branch of the company to explicitly tackle mental illness. The two companies will eventually create a library of molecules such as psilocybin, N, N-dimethyltryptamine (DMT) and other molecular derivatives.
Read more: Hot Penny Stocks To Watch That You Might Have Missed This Week
Apart from that, Enveric recently launched its PsyAI using artificial intelligence to offer predictive methodologies to identify molecules for new drug discovery from its molecular library, “Psybrary” as it is called.
What to watch with ENVB Stock this week
This week, however, it is not this transaction that is capturing the market’s attention. It also might not be the short 14.3% position that you might assume will be a focal point for short squeeze stock traders. This week, Enveric is exhibiting at 2 industry conferences. CEO Dr. Joseph Tucker will attend the AGPs Biotech & Specialty Pharma conference on October 13. He will also attend the KCSA Psychedelics Investor Conference on the same day.
Aditxt Inc. (NASDAQ: ADTX)
Another company focused on immune function is Aditxt. Its monitoring technology provides personalized information about each user’s immune system. At present, the company’s technology is in the preclinical stage, initially designed to combat organ transplant rejection and autoimmune diseases and allergies.
Read more: Top Tech Penny Stocks To Buy Right Now? 3 to watch
One of the more recent catalysts is its asset purchases from AiPharma. Why was it such a big event? These assets include a treatment called Avigan. It has received full marketing authorization or emergency use authorization in several markets for the treatment of COVID-19. These markets include Mexico, India, Malaysia, Thailand and Indonesia. In the UK, UAE, Greece, Hungary and Saudi Arabia, Avigan has been given the green light to sell under compassionate use programs. Keep in mind that this is in addition to the AditxtScore COVID-19 test previously launched by Aditxt.
What to watch with ADTX Stock this week
Following a binding agreement last week, Aditxt could be the center of attention again in the coming week. That’s because the company is showing up at the LD Micro Main Event on Wednesday. CEO Amro Albanna will also participate in 1-on-1 meetings with investors and analysts.
Penny Stocks This Week
Many more companies are ready to participate in this week’s industry presentations and conferences. These are just a few of those that have gained momentum in recent sessions. Looking for more penny stocks to watch this week with potential catalysts? Here is a list of some other names to know and dates to remember:
Clearside Biomedical (NASDAQ: CLSD) – October 9 and 11
Data from the Phase II ALTITUDE® trial of REGENXBIO in diabetic retinopathy patients treated with RGX-314 will be presented on October 9 and 11.
Lipocine Inc. (NASDAQ: LPCN) – October 12
The company is exhibiting at the HC Wainwright NASH Investor Conference on October 12. Lipocine focused on advancing its TLANDO platform for testosterone replacement therapy. A new drug application was resubmitted and confirmed by the FDA last month.
Hepion Pharmaceuticals (NASDAQ: HEPA) – October 12
Hepion will follow along with Lipocin as management will present at the HC Wainwright NASH conference. Hepion’s primary candidate, CRV431 is under clinical development for the treatment of NASH.
Tonix Pharmaceuticals (NASDAQ: TNXP) – October 13
This Wednesday, Tonix is participating in the AGP Biotech & Specialty Pharma conference. Management will participate in a roundtable discussion on the long COVID and COVID variants. Tonix is developing a portfolio of immunological treatments, including a COVID-19 platform to treat COVID, Long COVID and detect functional immunity of T cells to COVID.
Daré Bioscience (NASDAQ: DARE) – October 14
This week, Daré is participating in a roundtable at the DTC Perspectives Xpectives Health Summit on Thursday. The panel focuses on women’s health. Daré specializes in developing a portfolio of therapies and treatment options for contraception, fertility and women’s health in general.